To further investigate the impact of FXYD5 highly expressed TCs on CRC patients, we categorized patients in the TCGA cohort into high and low FTRS (FXYD5+ TCs risk score) groups based on the identified 8 prognostic genes. This evidence concerns the gene FXYD5 and colorectal carcinoma.